Requirement for YAP1 signaling in myxoid liposarcoma.

Adaptor Proteins, Signal Transducing / metabolism Animals Apoptosis / drug effects Cell Line, Tumor Cell Proliferation / drug effects Cellular Senescence / drug effects Chickens HEK293 Cells Humans Inhibitory Concentration 50 Liposarcoma, Myxoid / metabolism Mesenchymal Stem Cells / drug effects Mitosis / drug effects RNA Interference RNA-Binding Protein FUS / metabolism Signal Transduction / drug effects Transcription Factor CHOP / metabolism Transcription Factors / metabolism Verteporfin / pharmacology Xenograft Model Antitumor Assays YAP-Signaling Proteins
FUS‐DDIT3 Hippo pathway YAP1 myxoid liposarcoma verteporfin

Journal

EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380

Informations de publication

Date de publication:
05 2019
Historique:
pubmed: 23 3 2019
medline: 28 4 2020
entrez: 23 3 2019
Statut: ppublish

Résumé

Myxoid liposarcomas (MLS), malignant tumors of adipocyte origin, are driven by the

Identifiants

DOI: 10.15252/emmm.201809889 PMID: 30898787 PMC: PMC6505681
pubmed: 30898787
pii: emmm.201809889
doi: 10.15252/emmm.201809889
pmc: PMC6505681
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
DDIT3 protein, human 0
RNA-Binding Protein FUS 0
Transcription Factors 0
YAP-Signaling Proteins 0
YAP1 protein, human 0
Verteporfin 0X9PA28K43
Transcription Factor CHOP 147336-12-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2019 The Authors. Published under the terms of the CC BY 4.0 license.

Références

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20380-5
pubmed: 19091943
Oncogene. 2016 Feb 18;35(7):929-38
pubmed: 25961935
J Cell Mol Med. 2008 Aug;12(4):1347-59
pubmed: 18318690
Oncogene. 2009 Jan 15;28(2):270-8
pubmed: 18850010
Science. 2015 Nov 27;350(6264):1096-101
pubmed: 26472758
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
Sci Transl Med. 2011 Aug 31;3(98):98ra82
pubmed: 21885404
Leukemia. 2016 Dec;30(12):2409-2412
pubmed: 27560109
Cancer Cell. 2014 Aug 11;26(2):273-87
pubmed: 25087979
Nat Rev Cancer. 2013 Apr;13(4):246-57
pubmed: 23467301
Am J Pathol. 2006 May;168(5):1642-53
pubmed: 16651630
Oncotarget. 2016 May 24;7(21):30094-108
pubmed: 27129148
Dev Cell. 2010 Oct 19;19(4):491-505
pubmed: 20951342
Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12372-7
pubmed: 21746896
Am J Cancer Res. 2015 Dec 15;6(1):27-37
pubmed: 27073720
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Cancer Res. 2013 Apr 15;73(8):2518-28
pubmed: 23580575
G3 (Bethesda). 2017 Aug 7;7(8):2719-2727
pubmed: 28655737
Histopathology. 2014 Jan;64(1):38-52
pubmed: 24118009
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
Genes Chromosomes Cancer. 2010 Dec;49(12):1161-71
pubmed: 20842732
Clin Cancer Res. 2017 Oct 15;23(20):6227-6238
pubmed: 28637688
Cancer Res. 2006 Jul 15;66(14):7016-23
pubmed: 16849546
Nature. 2011 Jun 08;474(7350):179-83
pubmed: 21654799
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Oncogene. 2014 Oct 16;33(42):5006-16
pubmed: 24166495
Cancer Res. 2019 Jun 15;79(12):3125-3138
pubmed: 31000522
J Biol Chem. 2005 Feb 18;280(7):6170-80
pubmed: 15576374
Clin Cancer Res. 2001 Dec;7(12):3977-87
pubmed: 11751490
Am J Surg Pathol. 1996 Feb;20(2):171-80
pubmed: 8554106
Am J Pathol. 1997 Sep;151(3):735-44
pubmed: 9284822
Eur J Cancer. 2005 Dec;41(18):2853-60
pubmed: 16289617
Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):E3402-11
pubmed: 26080399
Cell. 2009 May 29;137(5):821-34
pubmed: 19490892
Genes Dev. 2007 Nov 1;21(21):2747-61
pubmed: 17974916
Curr Treat Options Oncol. 2017 Jun;18(6):34
pubmed: 28534249
Cancer Discov. 2014 Feb;4(2):216-31
pubmed: 24436047
Cell. 2015 Dec 3;163(6):1515-26
pubmed: 26627737
Cancer. 2016 Oct;122(19):2952-60
pubmed: 27434055
Exp Eye Res. 2014 Jul;124:67-73
pubmed: 24837142
Genes Chromosomes Cancer. 2013 Aug;52(8):775-84
pubmed: 23737213
Nat Genet. 2010 Aug;42(8):715-21
pubmed: 20601955
Nat Cell Biol. 2011 Aug 01;13(8):877-83
pubmed: 21808241
J Anat. 2009 May;214(5):759-67
pubmed: 19438770
Genes Dev. 2012 Jun 15;26(12):1300-5
pubmed: 22677547
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734
Mol Cancer Ther. 2019 Apr;18(4):834-844
pubmed: 30787173
Oncogene. 2000 May 11;19(20):2413-22
pubmed: 10828883
Cancer Discov. 2014 Nov;4(11):1326-41
pubmed: 25186949
Genes Chromosomes Cancer. 2011 Aug;50(8):644-53
pubmed: 21584898
J Clin Invest. 2014 Jan;124(1):285-96
pubmed: 24334454
Sci Signal. 2015 Oct 06;8(397):ra98
pubmed: 26443705

Auteurs

Marcel Trautmann (M)

Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
ORCID: 0000-0002-5842-1196

Ya-Yun Cheng (YY)

Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

Patrizia Jensen (P)

Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

Ninel Azoitei (N)

Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.

Ines Brunner (I)

Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jennifer Hüllein (J)

Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
Department of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID: 0000-0002-4421-5260

Mikolaj Slabicki (M)

Department of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Ilka Isfort (I)

Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
ORCID: 0000-0002-7485-8769

Magdalene Cyra (M)

Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
ORCID: 0000-0001-7738-2703

Ruth Berthold (R)

Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
ORCID: 0000-0001-7918-1657

Eva Wardelmann (E)

Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.

Sebastian Huss (S)

Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.

Bianca Altvater (B)

Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.
ORCID: 0000-0003-4936-4879

Claudia Rossig (C)

Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.
Cells in Motion Cluster of Excellence, University of Münster, Münster, Germany.
ORCID: 0000-0001-5853-8354

Susanne Hafner (S)

Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Hospital, Ulm, Germany.

Thomas Simmet (T)

Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Hospital, Ulm, Germany.

Anders Ståhlberg (A)

Department of Pathology and Genetics, Sahlgrenska Cancer Center, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden.
ORCID: 0000-0003-4243-0191

Pierre Åman (P)

Department of Pathology and Genetics, Sahlgrenska Cancer Center, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
ORCID: 0000-0002-1482-8875

Thorsten Zenz (T)

Department of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Hematology, Zurich University Hospital and University of Zurich, Zürich, Switzerland.
ORCID: 0000-0001-7890-9845

Undine Lange (U)

Department of Hematology, Medical Oncology and Pneumology, University Medical Center of Mainz, Mainz, Germany.

Thomas Kindler (T)

Department of Hematology, Medical Oncology and Pneumology, University Medical Center of Mainz, Mainz, Germany.
German Cancer Consortium, Heidelberg (Frankfurt/Mainz), Germany.

Claudia Scholl (C)

German Cancer Consortium, Heidelberg (Frankfurt/Mainz), Germany.
Division of Applied Functional Genomics, DKFZ, Heidelberg, Germany.

Wolfgang Hartmann (W)

Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany wolfgang.hartmann@ukmuenster.de stefan.froehling@nct-heidelberg.de.
Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
ORCID: 0000-0002-7609-5021

Stefan Fröhling (S)

Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany wolfgang.hartmann@ukmuenster.de stefan.froehling@nct-heidelberg.de.
German Cancer Consortium, Heidelberg (Frankfurt/Mainz), Germany.
ORCID: 0000-0001-7907-4595

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Eucaryotes › Animaux › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Vieillissement › Vieillissement de la cellule › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Oiseaux › Poulets › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Concentration inhibitrice 50 › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu conjonctif et des tissus mous › Sarcomes › Liposarcome › Liposarcome myxoïde › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches multipotentes › Cellules souches mésenchymateuses › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Phénomènes génétiques › Division du noyau cellulaire › Mitose › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Interférence par ARN › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines de liaison à l'ARN › Protéines à motif de reconnaissance de l'ARN › Ribonucléoprotéines nucléaires hétérogènes › Protéine FUS de liaison à l'ARN › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique et à glissière à leucines › Protéines liant les séquences stimulatrices de type CCAAT › Facteur de transcription CHOP › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Tétrapyrroles › Vertéporfine › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Requirement for YAP1 signaling in myxoid liposarcoma.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › Protéines de signalisation YAP › Requirement for YAP1 signaling in myxoid liposarcoma.